- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Steven Nathan Discusses the 2 Newly Approved Drugs to Treat IPF
The big news at the 2014 CHEST meeting in Austin, TX, was that 2 new drugs - pirfenidone and nintedanib - were approved to treat idiopathic pulmonary fibrosis, according to Steven Nathan, MD, medical director of the Lung Transplant Program at Inova Fairfax Hospital in Falls Church, VA.
The big news at the 2014 CHEST meeting in Austin, TX, was that 2 new drugs—pirfenidone and nintedanib—were approved to treat idiopathic pulmonary fibrosis (IPF), according to Steven Nathan, MD, medical director of the Lung Transplant Program at Inova Fairfax Hospital in Falls Church, VA.
Prior to these 2 drugs, which both slow the rate of decline of lung function, nothing had been approved to treat this fatal lung disease.
“[IPF] has a median survival of anywhere from 2-and-a-half to 5 years,” Dr Nathan explained. “So there’s been a lack of medical therapies for these conditions. So both of them offer some hope to patients with this condition.”
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
AI, GLP-1s Among Topics to Be Discussed During ASPC Annual Meeting
July 28th 2025The American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease Prevention features multiple sessions on different methods of treating and preventing cardiovascular disease, including through the use of artificial intelligence (AI) and glucagon-like peptide-1 (GLP-1) receptor agonists.
Read More
